CN117545508A - 用于癌的治疗和/或预防的药品 - Google Patents

用于癌的治疗和/或预防的药品 Download PDF

Info

Publication number
CN117545508A
CN117545508A CN202280044305.5A CN202280044305A CN117545508A CN 117545508 A CN117545508 A CN 117545508A CN 202280044305 A CN202280044305 A CN 202280044305A CN 117545508 A CN117545508 A CN 117545508A
Authority
CN
China
Prior art keywords
gln
chain variable
ser
variable region
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280044305.5A
Other languages
English (en)
Chinese (zh)
Inventor
冈野文义
赤泽大辅
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Toray Industries Inc
Original Assignee
Toray Industries Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toray Industries Inc filed Critical Toray Industries Inc
Publication of CN117545508A publication Critical patent/CN117545508A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
CN202280044305.5A 2021-06-23 2022-06-22 用于癌的治疗和/或预防的药品 Pending CN117545508A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2021-103818 2021-06-23
JP2021103818 2021-06-23
PCT/JP2022/024812 WO2022270523A1 (ja) 2021-06-23 2022-06-22 癌の治療及び／又は予防のための医薬品

Publications (1)

Publication Number Publication Date
CN117545508A true CN117545508A (zh) 2024-02-09

Family

ID=84545727

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280044305.5A Pending CN117545508A (zh) 2021-06-23 2022-06-22 用于癌的治疗和/或预防的药品

Country Status (10)

Country Link
US (1) US20240325529A1 (https=)
EP (1) EP4360648A4 (https=)
JP (1) JPWO2022270523A1 (https=)
KR (1) KR20240024074A (https=)
CN (1) CN117545508A (https=)
AU (1) AU2022296193A1 (https=)
BR (1) BR112023026985A2 (https=)
CA (1) CA3225420A1 (https=)
MX (1) MX2023014498A (https=)
WO (1) WO2022270523A1 (https=)

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
DE69535243T2 (de) 1994-07-13 2007-05-10 Chugai Seiyaku K.K. Gegen menschliches interleukin-8 gerichteter, rekonstituierter menschlicher antikörper
DK1069185T3 (da) 1998-04-03 2011-06-27 Chugai Pharmaceutical Co Ltd Humaniseret antistof mod human vævsfaktor (TF) og fremgangsmåde til at konstruere humaniseret antistof
DK1071700T3 (da) 1998-04-20 2010-06-07 Glycart Biotechnology Ag Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
CA2704600C (en) 1999-04-09 2016-10-25 Kyowa Kirin Co., Ltd. A method for producing antibodies with increased adcc activity
FR2807767B1 (fr) 2000-04-12 2005-01-14 Lab Francais Du Fractionnement Anticorps monoclonaux anti-d
CA2512729C (en) 2003-01-09 2014-09-16 Macrogenics, Inc. Identification and engineering of antibodies with variant fc regions and methods of using same
US8388955B2 (en) 2003-03-03 2013-03-05 Xencor, Inc. Fc variants
DE10359795A1 (de) 2003-12-19 2005-07-21 Bayer Technology Services Gmbh Strangverdampfervorrichtung
BRPI0911926A2 (pt) 2008-08-05 2020-08-18 Toray Industries, Inc composições farmacêuticas, anticorpos e usos de um anticorpo ou um fragmento do mesmo.
EP2711018A1 (en) 2009-06-22 2014-03-26 MedImmune, LLC Engineered Fc regions for site-specific conjugation
EP2480671B8 (en) 2009-09-22 2015-10-28 ProBioGen AG Process for producing molecules containing specialized glycan structures
DK2532680T3 (da) 2010-02-04 2015-07-20 Toray Industries Medicinsk sammensætning til behandling og/eller forebyggelse af cancer
HUE040012T2 (hu) 2010-02-04 2019-02-28 Toray Industries Gyógyászati ágens rák kezelésére és/vagy megelõzésére
DK2532366T3 (da) 2010-02-04 2017-01-02 Toray Industries Farmaceutisk sammensætning til behandling og/eller forebyggelse af cancer
US9115200B2 (en) 2010-02-04 2015-08-25 Toray Industries, Inc. Pharmaceutical composition for treating cancer using a monoclonal antibody having immunological reactivity with CAPRIN-1
CA2788545C (en) 2010-02-04 2019-03-26 Toray Industries, Inc. Pharmaceutical composition for treating and/or preventing cancer
RU2603742C2 (ru) 2010-02-04 2016-11-27 Торэй Индастриз, Инк. Фармацевтическая композиция для лечения и/или профилактики рака
JP2013528357A (ja) 2010-03-29 2013-07-11 ザイムワークス，インコーポレイテッド 強化又は抑制されたエフェクター機能を有する抗体
RU2595400C2 (ru) 2011-08-04 2016-08-27 Торэй Индастриз, Инк. Фармацевтическая композиция для лечения и/или профилактики злокачественной опухоли
PT2740489T (pt) 2011-08-04 2017-01-10 Toray Industries Composição farmacêutica para o tratamento e/ou a prevenção do cancro pancreático
US9181348B2 (en) 2011-08-04 2015-11-10 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prophylaxis of cancer
EP2740794B1 (en) 2011-08-04 2018-04-04 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prophylaxis of cancer
PT2740796T (pt) 2011-08-04 2017-07-26 Toray Industries Composição farmacêutica para o tratamento e/ou profilaxia de cancro
PL2740793T3 (pl) 2011-08-04 2018-04-30 Toray Industries, Inc. Kompozycja leku do leczenia i/lub zapobiegania nowotworowi
BR112014021103A2 (pt) 2012-02-21 2019-10-15 Toray Industries, Inc Anticorpo, composição farmacêutica, droga de combinação, dna, método de tratamento e uso de anticorpo
ES2739612T3 (es) 2012-02-21 2020-02-03 Toray Industries Composición farmacéutica para el tratamiento de cáncer
WO2013125654A1 (ja) 2012-02-21 2013-08-29 東レ株式会社 癌の治療及び／又は予防用医薬組成物
US9260513B2 (en) 2012-02-21 2016-02-16 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of cancer
JP6107654B2 (ja) 2012-03-30 2017-04-05 東レ株式会社 肝臓癌の治療及び／又は予防用医薬組成物
WO2013147176A1 (ja) 2012-03-30 2013-10-03 東レ株式会社 胆嚢癌の治療及び／又は予防用医薬組成物
CN112587671A (zh) 2012-07-18 2021-04-02 博笛生物科技有限公司 癌症的靶向免疫治疗
AU2014303375B2 (en) 2013-08-09 2019-07-04 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of cancer
AU2019242520B2 (en) * 2018-03-30 2026-02-26 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of cancer

Also Published As

Publication number Publication date
WO2022270523A1 (ja) 2022-12-29
MX2023014498A (es) 2024-01-25
AU2022296193A1 (en) 2024-01-18
EP4360648A1 (en) 2024-05-01
BR112023026985A2 (pt) 2024-03-12
EP4360648A4 (en) 2025-10-08
CA3225420A1 (en) 2022-12-29
KR20240024074A (ko) 2024-02-23
JPWO2022270523A1 (https=) 2022-12-29
US20240325529A1 (en) 2024-10-03

Similar Documents

Publication Publication Date Title
CN113347994B (zh) 使用her3抗原结合分子治疗和预防癌症
CN109476746B (zh) Egfr结合分子
CN109071666B (zh) 人脊髓灰质炎病毒受体(pvr)特异性抗体
EP3193931B1 (en) Neutralization of inhibitory pathways in lymphocytes
EP3193929B1 (en) Treatment regimens using anti-nkg2a antibodies
KR101801667B1 (ko) 암의 치료 및/또는 예방용 의약 조성물
KR101805520B1 (ko) 암의 치료 및/또는 예방용 의약 조성물
AU2007324509B2 (en) Novel antiproliferation antibodies
AU2019242520A1 (en) Pharmaceutical composition for treatment and/or prevention of cancer
KR20190035863A (ko) 암 치료를 위한 항Siglec-7 항체
KR20170070076A (ko) 항-ｎｋｇ2ａ 제제를 이용하는 암 치료
KR20220152318A (ko) 암의 치료 및/또는 예방을 위한 의약품
CN114181310A (zh) 抗tigit抗体、其药物组合物及用途
JP2023531042A (ja) ４－１ｂｂ結合タンパク質及びその用途
CN117460532A (zh) 用于癌的治疗和/或预防的药品
TW202334228A (zh) B7h6抗體及其應用
KR20220151684A (ko) 암의 치료 및/또는 예방을 위한 의약품
KR20220152309A (ko) 암의 치료 및/또는 예방을 위한 의약품
KR20220153621A (ko) 암의 치료 및/또는 예방을 위한 의약품
RU2761638C1 (ru) Антитела против лиганда программируемой смерти (pd-l1) и их применение
WO2021032174A1 (zh) 一种抗cd47抗原结合蛋白及其应用
CN120239710A (zh) 抗ccr8抗体及其用途
KR20220153615A (ko) 암의 치료 및/또는 예방을 위한 의약품
CN117545508A (zh) 用于癌的治疗和/或预防的药品
RU2781542C2 (ru) Фармацевтическая композиция для лечения и/или профилактики злокачественной опухоли

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination